Fundraising FoxBird Rock Bio
AcquiredLa Jolla, US · Delaware corporation · 2 known investors
Find your way into Bird Rock Bio
Sign up to see every warm intro you have to Bird Rock Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bird Rock Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Skye Bioscience August 2023 · $15.6M ($15.6 million) · source ↗
Bird Rock Bio was a La Jolla, CA clinical-stage biopharmaceutical company developing antibody-based drugs targeting GPCRs, including nimacimab, a CB1-receptor antibody for fibrotic and metabolic diseases.
Founders & leadership
RN
Richa NandExecutive
AG
Alan GlicklichExecutive
MS
Mark SaadExecutive
PA
Paul A. GraysonExecutive
EK
Erik KarrerExecutive
RS
Ray StevensNamed on SEC filing
Board
BB
Bradley BolzonBoard director
SN
Simon NebelBoard director
SG
AM
Allan MarchingtonBoard director
RB
Roel BulthuisBoard director
AJ
Investors · 2
5AM Ventureslisted by 5AM VenturesSan Francisco · $100K – $4M
How we know: 5AM Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$12.5M disclosed across 3 rounds · 2014–2016
▶$2.5MraisedJan 2017 · 1 investors · OtherRule 506(b)
▶$2.5MraisedJan 2017 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Simon NebelDirector
- Mark SaadExecutive Officer
- Simeon GeorgeDirector
- Allan MarchingtonDirector
- Bradley BolzonDirector
- Peppi PresitDirector
- Andrew J. SchwabDirector
- Paul A. GraysonExecutive Officer, Director
- Ray StevensDirector
- Alan GlicklichExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedFeb 2016 · 8 investors · OtherRule 506(b)
▶$5MraisedFeb 2016 · 8 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Peppi PresitDirector
- Richa NandExecutive Officer
- Bradley BolzonDirector
- Ray StevensDirector
- Simon NebelDirector
- Simeon GeorgeDirector
- Alan GlicklichExecutive Officer
- Allan MarchingtonDirector
- Roel BulthuisDirector
- Mark SaadExecutive Officer
- Paul A. GraysonExecutive Officer, Director
- Andrew J. SchwabDirector
- Offering amount
- $30M
- Amount sold
- $5M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMar 2014 · 8 investors · OtherRule 506(b)
▶$5MraisedMar 2014 · 8 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Allan MarchingtonDirector
- Simon NebelDirector
- Simeon GeorgeDirector
- Bradley BolzonDirector
- Paul A. GraysonExecutive Officer, Director
- Roel BulthuisDirector
- Erik KarrerExecutive Officer
- Andrew J. SchwabDirector
- Peppi PresitDirector
- Ray StevensDirector
- Offering amount
- $15M
- Amount sold
- $5M
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Bird Rock Bio do?
- Bird Rock Bio was a La Jolla, CA clinical-stage biopharmaceutical company developing antibody-based drugs targeting GPCRs, including nimacimab, a CB1-receptor antibody for fibrotic and metabolic diseases.
- Who are Bird Rock Bio's investors?
- Bird Rock Bio's investors include 5AM Ventures, SR One Capital Management.
- How much funding has Bird Rock Bio raised?
- Bird Rock Bio has disclosed $12.5M raised across 3 rounds.
- Where is Bird Rock Bio headquartered?
- Bird Rock Bio is headquartered in La Jolla, US.